Keyphrases
Fragrance Ingredient
69%
Ingredient Safety
66%
CAS Registry
65%
Safety Assessment
65%
Local Respiratory Toxicity
32%
Phototoxicity
31%
Chronic Obstructive Pulmonary Disease
28%
Repeated Dose Toxicity
28%
Photoallergenicity
27%
Skin Sensitization
25%
Asthma
24%
Toxicity Endpoints
23%
Reproductive Toxicity
23%
Forced Expiratory Volume in 1 Second (FEV1)
22%
Mycobacterium Tuberculosis (M. tb)
22%
COVID-19
21%
Threshold of Toxicological Concern
20%
Lung Cancer Screening
20%
Environmental Safety
18%
Genotoxicity
18%
Lung Function
17%
Eosinophils
17%
Airway Hyperresponsiveness
17%
Confidence Interval
17%
Spirometry
15%
Lung Cancer
14%
Tuberculosis
14%
Lung
14%
Cramer Class
14%
Mucosal-associated Invariant T Cells
13%
United States
13%
Hospitalization
12%
North America
11%
Developmental Toxicity
11%
Lung Health
11%
Environmental Standards
11%
Dermal Sensitization Threshold
11%
Burden of Obstructive Lung Disease
10%
Europe
10%
Smokers
10%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
10%
Airway Obstruction
10%
Risk Quotient
10%
Risk Factors
10%
Information Support
10%
Pulmonary Surfactant
10%
Phototoxic
10%
Critically Ill Patients
9%
Fragrance
9%
Smoking Cessation
9%
Airway
9%
Bioaccumulative
9%
Predicted Environmental Concentrations
8%
Palliative Care
8%
Predicted No Effect Concentration
8%
Food Toxicology
8%
Software Vulnerability
8%
Chemical Toxicology
8%
Post-bronchodilator
8%
Intensive Care Unit
8%
Guinea pig
8%
CD8+ T Cells
8%
Bronchoconstriction
8%
Pulmonary Nodule
8%
Health Studies
7%
Odds Ratio
7%
Regret
7%
Vaccine Effectiveness
7%
Bronchiectasis
7%
Veterans Health Administration
7%
T Cells
7%
Repeated Dose
7%
Finished Product
7%
M2 muscarinic Receptor
7%
Methyl
7%
Airway Sensory Nerves
7%
Quality of Life
6%
Pulmonary Function
6%
Electronic Health Records
6%
Skin Sensitization Potential
6%
Nerve
6%
Adjusted Odds Ratio
6%
Population-based Study
6%
Antigen Presentation
6%
Reactive Materials
6%
Invasive Mechanical Ventilation
6%
Placebo
6%
Clinical Trials
6%
Parasympathetic Nerve
6%
Apologizing
6%
Inconvenience
6%
Veterans Affairs
5%
Cough
5%
UV Spectra
5%
Respiratory Symptoms
5%
Randomized Clinical Trial
5%
Cigarette Smoking
5%
American Thoracic Society
5%
Adsorption
5%
Chronic Airflow Obstruction
5%
Medicine and Dentistry
COVID-19
70%
Chronic Obstructive Pulmonary Disease
66%
Disease
44%
Lung Cancer
43%
Clinician
41%
Asthma
39%
Lung Cancer Screening
36%
Symptom
31%
Intensive Care Unit
29%
Prevalence
26%
Obstructive Lung Disease
24%
Extracorporeal Membrane Oxygenation
23%
Smoking
22%
Intensive Care
21%
Electronic Health Record
20%
Spirometry
20%
Airway Obstruction
20%
Placebo
19%
Bronchiectasis
19%
Observational Study
19%
Lung Nodule
17%
Infection
17%
Odds Ratio
17%
Malignant Neoplasm
16%
Clinical Trial
15%
Symptomatic Treatment
15%
Systematic Review
15%
Acute Respiratory Distress Syndrome
15%
Coughing
14%
Artificial Respiration
14%
Bronchodilating Agent
14%
Low Drug Dose
14%
Cystic Fibrosis
13%
Quality of Life
13%
Veterans Affairs
12%
Nicotine Withdrawal
12%
Silo-Filler's Disease
12%
Non Small Cell Lung Cancer
12%
Primary Health Care
12%
Health Care
11%
Sepsis
11%
Computer Assisted Tomography
11%
Health Care Cost
10%
Intubation
10%
Randomized Controlled Trial
10%
Respiratory Disease
10%
Randomized Clinical Trial
9%
Bronchoconstriction
9%
Intensive Care Medicine
9%
Forced Expiratory Volume
9%
Stereotactic Body Radiation Therapy
8%
Dyspnea
8%
Forced Vital Capacity
8%
Drug Therapy
8%
Chronic Cough
8%
Hypertensive Factor
8%
Diagnosis
8%
Veterans Health
8%
Respiratory Care
8%
Hazard Ratio
8%
Pulmonary Hypertension
8%
Decision Making
7%
Lung Function
7%
Tracheal Intubation
7%
Surgery
7%
Resuscitation
7%
Cohort Analysis
7%
Logistic Regression Analysis
7%
Shared Decision Making
6%
Wheeze
6%
Burnout
6%
Life Sustaining Treatment
6%
COVID-19 Vaccine
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Influenza Vaccine
6%
Tuberculosis
6%
Extracorporeal Life Support
6%
Eosinophil
6%
Cohort Effect
6%
Combination Therapy
6%
Adverse Event
6%
Low and Middle Income Countries
6%
Critical Illness
6%
Patient Care
6%
Emergency Department
6%
Mucosal-Associated Invariant T Cell
6%
Heparin
6%
Acute Kidney Injury
6%
Medicare
5%
Respiratory Tract Allergy
5%
Outpatient
5%
Peak Expiratory Flow
5%
Prospective Cohort Study
5%
Patient Referral
5%
Receptor
5%
Shock (Circulatory)
5%
Public Health
5%
Screening
5%
Cancer Risk
5%
Pharmacology, Toxicology and Pharmaceutical Science
Safety Assessment
100%
Chronic Obstructive Lung Disease
96%
Lung Toxicity
62%
Phototoxicity
61%
Asthma
56%
Photoallergy
55%
Dose Toxicity
51%
Reproductive Toxicity
44%
Disease
43%
Genotoxicity
38%
Prevalence
35%
Symptom
35%
Placebo
27%
Lung Cancer
24%
Environmental Standard
23%
Airway Obstruction
20%
Coughing
19%
Bronchodilating Agent
17%
Infection
16%
Inflammation
14%
Guinea Pig
14%
Predicted Environmental Concentration
14%
Coronavirinae
13%
Developmental Toxicity
12%
Randomized Clinical Trial
12%
Receptor
12%
Chronic Cough
11%
Clinical Trial
11%
Acetylcholine
11%
Bronchoconstriction
10%
Dyspnea
10%
SARS Coronavirus
10%
Bronchiectasis
10%
mRNA Vaccine
9%
Cohort Study
9%
Respiratory Tract Disease
9%
Adult Respiratory Distress Syndrome
9%
Vaccination Policy
9%
Surfactant
8%
COVID-19 Vaccine
8%
Lung Disease
8%
Observational Study
8%
Respiratory Tract Allergy
7%
Chronic Bronchitis
7%
Influenza Vaccine
7%
Hypertensive Factor
7%
Pulmonary Hypertension
7%
Comorbidity
7%
Wheezing
6%
Pulmonary Surfactant
6%
Cystic Fibrosis
6%
Mouse
6%
Muscarinic Receptor
6%
Occupational Exposure
6%
Tumor Necrosis Factor
6%
Methacholine
6%
Randomized Controlled Trial
6%
Emphysema
6%
Heparin
6%
Intubation
6%
Muscarinic M2 Receptor
5%
Adverse Event
5%
Cytokine
5%
Alpha 1 Antitrypsin Deficiency
5%